Novel treatments of autosomal dominant polycystic kidney disease.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  American Society of Nephrology. Clinical Journal

• Publication date

  2014-05-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.2215/CJN.02480314PMID 24721886PMCID PMC4011435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care

  2015cited by this paper
• Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.

  2014cited by this paper
• Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

  2014cited by this paper
• Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

  2014cited by this paper
• Autosomal dominant polycystic kidney disease.

  2014cited by this paper
• Hypertension in autosomal dominant polycystic kidney disease

  2013cited by this paper
• Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

  2013cited by this paper
• Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

  2013cited by this paper
• Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.

  2013cited by this paper
• Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease

  2013cited by this paper
• Renal disease progression in autosomal dominant polycystic kidney disease

  2012cited by this paper
• Tolvaptan in patients with autosomal dominant polycystic kidney disease.

  2012cited by this paper
• Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.

  2012cited by this paper
• Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease

  2012cited by this paper
• mTOR inhibitors and autosomal dominant polycystic kidney disease.

  2011cited by this paper
• Sirolimus therapy to halt the progression of ADPKD.

  2010cited by this paper
• Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

  2010cited by this paper
• Treatment strategies and clinical trial design in ADPKD.

  2010influential reference
• The HALT polycystic kidney disease trials: design and implementation.

  2010cited by this paper
• Hypertension in autosomal dominant polycystic kidney disease.

  2010cited by this paper
• Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

  2010cited by this paper
• Cyclic nucleotide signaling in polycystic kidney disease.

  2010cited by this paper
• Everolimus in patients with autosomal dominant polycystic kidney disease.

  2010cited by this paper
• Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study.

  2009cited by this paper
• Prospective change in renal volume and function in children with ADPKD.

  2009cited by this paper
• Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

  2009cited by this paper
• A case for water in the treatment of polycystic kidney disease.

  2009cited by this paper
• Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.

  2009cited by this paper
• Therapy for polycystic kidney disease? It's water, stupid!

  2008cited by this paper
• Clinical practice. Autosomal dominant polycystic kidney disease.

  2008cited by this paper
• Vasopressin directly regulates cyst growth in polycystic kidney disease.

  2008cited by this paper
• Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

  2007cited by this paper
• Increased water intake decreases progression of polycystic kidney disease in the PCK rat.

  2006cited by this paper
• Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

  2006cited by this paper
• The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.

  2006cited by this paper
• Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

  2005cited by this paper
• Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.

  2005cited by this paper
• Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.

  2005cited by this paper
• Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

  2004cited by this paper
• Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

  2003cited by this paper
• Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

  2003cited by this paper
• Molecular genetics of autosomal dominant polycystic kidney disease.

  2003cited by this paper
• Cyst decompression surgery for autosomal dominant polycystic kidney disease.

  1992cited by this paper
• Autosomal dominant polycystic kidney disease

  1992cited by this paper
• The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.

  1990cited by this paper
• Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats.

  1982cited by this paper

• Diseases of the Kidney

  2020cites this paper
• Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease

  2019cites this paper
• Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey

  2017cites this paper
• Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists

  2016cites this paper
• Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.

  2015cites this paper
• Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trials: A Critical Appraisal

  2015cites this paper
• Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care

  2015cites this paper